Meet Dr. Kenneth Mankowski

Kenneth A. Mankowski, D.O., Board-certified Neurologist

Kenneth A. Mankowski, DO, is a board-certified neurologist specializing in the diagnosis and treatment of multiple sclerosis (MS) and general neurological conditions. Dr. Kenneth Mankowski offers the diagnosis and treatment of conditions that affect the brain, spinal cord and nerves throughout the body. He has a special interest in working with patients with multiple sclerosis (MS).

My Pledge

As the Founder of CNS & MS Institute, my pledge is immediate same day access to a Board Certified Neurologist specializing in MS with a goal to identify Multiple Sclerosis (MS) and rapidly institute an effective comprehensive treatment strategy within 1-2 weeks of contact.


Dr. Kenneth Mankowski received his Doctor of Osteopathic Medicine degree in 1995 from The University of Health Sciences College of Osteopathic Medicine in Kansas City, Missouri.

Dr. Mankowski completed an internal medicine internship and a one year emergency medicine residency at Mount Clemens General Hospital in Mount Clemens, Michigan. He subsequently completed a residency in neurology at Botsford General Hospital (affiliated with Michigan State University) in Farmington Hills, Michigan, He also completed a fellowship in neurophysiology and neuromuscular disorders with a focus on electromyography (EMG) and electroencephalography (EEG) testing at Henry Ford Hospital in Detroit, Michigan.

  • Board Certified Neurologist since 2002 
  • CNS & MS Institute President & Founder 
  • Medical Director of Decillion Healthcare (Infusion Center) 
  • MS Society Advisory Board Member 
  • Fellowship Trained 
  • Accomplished Lecturer 
  • Research Trials 
  • Neurology Residency Trainer



  • Hillsdale College
    Hillsdale, Michigan
    08/1986 to 12/1988
  • University of Michigan
    B.A. Psychology- magna cum laude
    National Honors Society, Psychology
    01/1989 to 06/1991


The University of Health Sciences
College of Osteopathic Medicine
Kansas City, Missouri USA
Doctor of Osteopathy 08/1991 to 06/1995


Henry Ford Hospital
Detroit, Michigan
Neurophysiology – Neuromuscular 09/2000 to 02/2001


  • American Osteopathic Association 
  • American College of Osteopathic Neurologists and Psychiatrists (ACN/ACONP) 
  • Medical Forum 
  • Hospital Staff
    > Riverside Methodist Hospital, Columbus, Ohio
    > Berger Hospital, Circleville, Ohio


Clinical Studies:

  • A Multi-Center, Randomized, Blinded, Parallel-Group Study of Avonex Compared with Avonex in Combination with Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Breakthrough Disease on Avonex Monotherapy (Avonex Combination Therapy- “ACT” Protocol C-865) awarded January 2004 by Biogen Idec 
  • A Double Blind, Multi-Center, Randomized, Placebo Controlled Single Dose Study to Evaluate the Safety and Efficacy of TreximaTM in the Acute Treatment of Migraine Headaches (MT400-302) awarded July 2004 by Pozen. 
  • Protocol TNC GA MS 2004 01: A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the Add-On Effect of Oral Steroids In Relapsing Remitting Multiple Sclerosis Subjects Treated with Glatiramer Acetate (GA). 
  • Factors That Influence Adherence with Disease-Modifying Therapy in Multiple Sclerosis. This retrospective study was undertaken to determine which factors are most critical in affecting strict adherence to DMT injection schedules. A secondary objective included identifying differences in patient adherence treated by academic larger sites versus smaller community sites. 
  • Biogen Idec- Protocol ID 101-MS-407 Strive: An observational study of Tysabri in early Relapsing/Remitting MS on anti-JCV antibody negative patients. 
  • Biogen Idec - Study Protocol ID 101-MS-402 Tygris Tysabri 
  • Biogen Idec-Protocol ID 101-JC-402 Stratify JCV Antibody Program in patients with Relapsing MS receiving or considering treatment with Tysabri. 
  • Biogen Idec Protocol ID 101-JC-402 Focused Group JC Positive High Risk Population Study. 
  • ANCHOR CD Protocol ID TL-52120-156 Dysport for Injection AbototulinumtoxinA Neurotoxin Clinical & Health Economics Outcomes Registry in Cervical Dystonia. 
  • Completed Good Clinic Practice Training-3/18/2013. 
  • A Phase 2, Randomized, Multi-Center, Parallel-group, Rater-Blinded study to evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg, and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis (EMR200575-001 Pathway 1) 
  • A multinational, multicenter, randomized, double-blind, parallel-group, placebocontrolled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/ day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS). 
  • (Phase 3: LAQ-MS-305 Concerto) 
  • Avanir Protocol 12-AVR-401. Phase 4 Interventional trial to assess the safety, tolerability and effectiveness of NUEDEXTA (Dextromethorphan 20mg/ Quinidine10mg) in the treatment of Pseudobulbar Affect (PBA) in patients with stroke, TBI and dementia. 
  • Biogen Idec-STRATEGY-Protocol ID 109MS412. Phase IV-Evaluate clinical outcomes in RRMS patients who transition from Tysabri to Tecfidera. 
  • SunPharma Protocol CLR_09_21 and CLR_11_04-Phase III-Demonstrate the efficacy of Baclofen ER for spasticity in patients with RRMS.


  • September 23, 2015, Disease state education, Peer to Peer 
  • September 17, 2015, Individualized Relapsing MS Treatment with an Evidence based Oral Therapy, Peer to Peer 
  • August 7, 2015, Journal Club- Grand Rounds, Grandview Hospital Residency Program- Neurology 
  • August 24,2015, Monitoring disease progression and identifying breakthrough disease, Peer to Peer 
  • August 18, 2015, Life with MS, Patient Program 
  • March 12, 2015, American College of Neuropsychiatrists- Update in Multiple Sclerosis 
  • January 7, 2015, American College of Osteopathic Primary Care Physician's- Multiple Sclerosis diagnosis and prognostic indicators 
  • March 12, 2015, American College of Osteopathic Neurology- Update in Multiple Sclerosis 
  • March 14, 2013, American College of Osteopathic Neurology- Multiple Sclerosis Therapeutics 
  • January 2010, Ohio Ophthalmology Society, Multiple Sclerosis – Early Diagnosis and Treatment 
  • March 7, 2006, American College of Osteopathic Family Physicians, Updates in Multiple Sclerosis Treatments and Pathophysiology 
  • March 18, 2006, American College of Osteopathic Neurology, Head trauma: Pathophysiology and Treatment. 
  • April 2002 to 2014, Presented greater than 150 lectures to audiences including both patients and Neurologist 
  • Sponsored by:
    > Biogen Idec
    > Teva Neuroscience
    > Genzyme
    > M.S. Society
    > Mount Carmel Foundation
    > CNS & MSI
    > Accorda
    > National MS Society
    > Medical Forum 
  • June 2001, June 2002, June 2014, June 2015 Emergency Department Grand Rounds- Multiple Sclerosis in the ED update, Mt. Clemens General Hospital